ReviewHealth science reports2026
Effectiveness and Safety of Nirmatrelvir/Ritonavir (Paxlovid) Versus Remdesivir in COVID-19: A Systematic Review and Meta-Analysis of Retrospective Studies.
Review in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Nirmatrelvir/ritonavir (Paxlovid) and remdesivir are antiviral agents that have been widely used in the management of patients with Coronavirus disease 2019 (COVID-19). This systematic review and meta-analysis were conducted to compare the clinical effectiveness and safety outcomes of Paxlovid and remdesivir among patients with COVID-19. Methods: A systematic search was performed across the Cochrane Library, Web of Science, PubMed, and medRxiv from inception to July 2024. Data from the identified studies were analyzed using Comprehensive Meta-Analysis (CMA) software. Results: Thirteen studies involving 4583 patients were included in the final analysis. Compared with remdesivir, Paxlovid was associated with a significant reduction in mortality (odds ratio [OR] = 0.36, 95% confidence interval [CI]: 0.18-0.73), time to SARS-CoV-2 negative conversion (standardized mean differences [SMD] = -1.44, 95% CI: -1.54 to -1.33), hospitalization (OR = 0.34, 95% CI: 0.16-0.74), intensive care unit admission (OR = 0.10, 95% CI: 0.01-0.53), and the need for oxygen therapy (OR = 0.06, 95% CI: 0.02-0.16). No statistically significant difference was observed between the two treatments regarding polymerase chain reaction negativity rate (OR = 1.45, 95% CI: 0.73-2.86). However, adverse events were higher among patients receiving Paxlovid (OR = 6.60, 95% CI: 3.24-13.42). The certainty of evidence for the evaluated outcomes ranged from low to moderate. Conclusion: In patients with COVID-19, Paxlovid may offer potential benefits over remdesivir for certain clinical outcomes, though it may also be accompanied by a higher rate of adverse events. These findings are based on retrospective studies, which carry risks of selection bias, confounding, and heterogeneity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.